LONG-COVIDNCT05225688
Skeletal Muscle in PASC and ME/CFS Patients
An observational study of LONG-COVID and Post-acute Sequelae of COVID-19, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 1 site in Netherlands.
Trial summary
Rationale: A common feature in patients with Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) and Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are skeletal muscle-related symptoms, such as muscle pain, weakness, fatigue and post-exertional malaise. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- LONG-COVID, Post-acute Sequelae of COVID-19, ME/CFS
- What is being tested?
- Bike exertion test
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 81 participants
- Where
- 1 siteNetherlands
- Study dates
- 3 Jan 2022to 1 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: 26 non-hospitalized participants with diagnosed PASC, 26 patients with ME/CFS and 30 healthy participants of similar sex, age, BMI and preferably current physical activity levels between the ages of 18-65 years old will be recruited to the study.
Who may be able to join
- In order to be eligible to participate in this study, a subject with PASC must meet all of the following criteria:
- Non-hospitalized individuals with prior confirmed diagnosis of severe acute respiratory coronavirus 2 (SARS-CoV-2) infection by reverse transcription-polymerase chain reaction testing or serology (wantai) testing
- Individuals with diagnosed PASC by a post-covid physician
- >3 months of symptoms
- Post exertional malaise, according to the DSQ-PEM questionnaire or 1:1 interview with post-covid physician
- No symptoms present before confirmed diagnosis of severe acute respiratory coronavirus 2
Show all 16Show fewer
- Aged between 18-65 years
- In order to be eligible to participate in this study, a subject with ME/CFS must meet all of the following criteria:
- Fulfill the Canadian Consensus Criteria (CCC)
- Post exertional malaise, according to the DSQ-PEM questionnaire or 1:1 interview with post-covid physician
- >3 months of symptoms
- Aged between 18-65 years
- Confirmed diagnosis of severe acute respiratory coronavirus2 (SARS-CoV-2) infection by reverse transcription-polymerase chain reaction testing or serology (wantai) testing
- For the healthy controls:
- Aged between 18-65 years
- Confirmed diagnosis of severe acute respiratory coronavirus2 (SARS-CoV-2) infection by reverse transcription-polymerase chain reaction testing or serology (wantai) testing without admission
Who cannot join
- A potential subject who meets any of the following criteria will be excluded from participation in this study:
- History of asthma, stroke, chronic obstructive pulmonary disease, congestive heart failure, heart surgery, or congenital heart diseases
- Severe illness (e.g., active malignancy, CHD, uncontrolled diabetes)
- Current treatment with drugs known to interfere with metabolism e.g. systemic corticosteroids, statins, SGLT2 inhibitors, GLP1 receptor agonists or immune modulatory drugs in the last three months.
- Severe psychiatric or mood disorders
- Insulin pump therapy
Show all 20Show fewer
- Symptomatic autonomic or distal neuropathy
- BMI >35 due to adiposity, since this is known to cause difficulties in obtaining muscle biopsies.
- Pregnancy
- Recent acute myocardial infarction (<6 months)
- Uncontrolled arrhythmia/severe conduction disorder (atrial fibrillation or second/third degree AV block) causing hemodynamic compromise
- Implantable pacemaker or other cardiac device with complete ventricular pacing
- Uncontrolled heart failure with hemodynamic compromise
- Uncontrolled hypertension (Systolic Blood Pressure >150 mmHg and Diastolic Blood Pressure > 100 mmHg on repeated measurements)
- Active infection, anaemia, severe renal dysfunction (estimated Glomerular filtration rate <30 ml/min/1,73m2) likely to significantly impact on exercise performance
- Chronic illness (including orthopaedic, endocrinological, haematological, malignant, gastrointestinal, neurological, muscle or inflammatory disorders) likely to significantly impact on exercise performance
- > 6 alcohol units per day or >14 alcohol units per week
- Use of anticoagulants or anti platelet therapy
- For the healthy controls:
- ● Individuals hospitalized in the last 6 months (i.e. after SARS-CoV-2 infection).
Trial locations and contacts
1 site in 1 country.
Netherlands1 site
Amsterdam university medical centre AMC
Amsterdam, North Holland, 1105AZ
About this study
Official title: Skeletal Muscle Structure and Function in Relation to Post-exertional Malaise in Patients With PASC and ME/CFS
Rationale: A common feature in patients with Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) and Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are skeletal muscle-related symptoms, such as muscle pain, weakness, fatigue and post-exertional malaise.
Objective: The primary aim is to determine markers for skeletal muscle structure and function, and circulating factors, in patients with PASC and ME/CFS, and compare with controls. The secondary objective is to determine skeletal muscle structure and function before and after induction of post-exertional malaise, and assess the relationships between the measures obtained from muscle biopsies and parameters of exercise tolerance.
Read more
Study design: Case-control observational study
Study population: Patients with PASC, ME/CFS and healthy human volunteers, 18 - 65 yr old.
Intervention (if applicable): none
Main study parameters/endpoints: Primary outcome parameters are markers for local inflammation, viral infiltration, mitochondrial respiratory function and myokine concentrations in a muscle biopsy and venous blood before and after induction of post-exertional malaise. Heart rate variability and measures of exercise performance will also be determined.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Participants will be asked to perform physical exercise tests, give muscle biopsies (2 samples), and various blood samples. There is some extent of burden and risk associated with harvesting muscle biopsies and blood samples, however this will be mitigated by the fact that these procedures will only be carried out by trained physicians. Moreover, the scientific gain from obtaining intracellular information outweighs these relatively quick procedures with minimal discomfort afterwards. The acute risks of the physical exercise measurements are negligible. The main risk for patients is that these patients often suffer from post-exertional malaise, which causes the participants to feel fatigued for some time after the maximal exercise test. It is one of the aims to better understand post-exertional malaise.
Read the detailed description
- INTRODUCTION AND RATIONALE Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) are severely debilitating diseases mainly characterized by chronic fatigue, post-exertional malaise (PEM) and cognitive impairment with autonomic, neuro-endocrine, immunological and cognitive involvement(Davis et al. 2021; Deumer et al. 2021; Soares et al. 2022). The clinical presentation of both diseases is remarkably overlapping. Particularly, skeletal muscle-related complaints, such as extreme fatigue, muscle weakness and muscle pain, are symptoms that tremendously decrease the patients quality of life and overlap in both patient groups, The key symptom, PEM, distinguishes PASC and ME/CFS from other more common fatigue conditions and is characterized by worsening or relapse of symptoms (including sleep dysfunction, cognitive impairment and extreme skeletal muscle fatigue) after physical activity, which can last for days or weeks(Davis et al. 2021; Soares et al. 2022; Stussman et al. 2020). We recently reviewed the skeletal muscle alterations in both acute SARS-CoV-2 infection and patients with Long COVID, and concluded that post-exertional malaise in patients with Long COVID cannot be explained by current knowledge on skeletal muscle structure and function(Soares et al. 2022). A possible lead to the understanding of PEM in Long COVID and ME/CFS pathophysiology is provided by the observation that most cases appear to have an infectious onset(Choutka et al. 2022; Magnus et al. 2015; Tsai et al. 2014). Following SARS-CoV-2 infection, 10-30% of patients exhibit post-infectious fatigue syndrome, called Long COVID or post-COVID condition(Ballering et al. 2022). PEM is the hallmark symptom of Long COVID and ME/CFS and a criterion for CCC, ICCC and IOM case definitions. Little is known about the underlying pathophysiology of skeletal muscle abnormalities, including PEM. No treatment options are available, apart from the advice to patients to avoid exercise or exercise below an (unknown) threshold. Due to the heterogeneity of patients, these muscle-related symptoms may vary dramatically, and is likely multifactorial in nature. Whilst long-term consequences of hospitalization are known, the widespread incidence of muscle-related symptoms suggests that skeletal muscle adaptations seen in non-hospitalized patients with PASC and ME/CFS stand apart from those seen in critical illness myopathy. The muscle weakness can range from mild to severe, and such symptoms may persist long after the viral infection has resolved. The high prevalence of skeletal muscle-related symptoms hint towards structural and functional alterations in skeletal muscle in patients with PASC and ME/CFS(Kerkhoff et al. 2022; McGregor et al. 2019; Noor et al. 2021). In this study, we aim to study alterations in intracellular skeletal muscle structure and function and the immune response that will help to explain why patients with PASC and ME/CFS suffer from post-exertional fatigue.
- OBJECTIVES To obtain insight whether skeletal muscle adaptations can explain post-exertional fatigue malaise in patients with PASC and ME/CFS, the present study will address the following objectives: Primary objectives:
- To determine markers for skeletal muscle structure and function (such as mitochondrial ultrastructure and function, viral infiltration, metabolite concentrations, myokine secretion), the immune response and circulating myokines (muscle-derived molecules), in non-hospitalized patients with PASC, ME/CFS and healthy controls. Secondary objectives:
- To determine each of the above variables both before and after induction of post-exertional malaise, and assess the relationships between the measures obtained from muscle biopsies and parameters of exercise tolerance.
- STUDY DESIGN 3.1. General. Case-control study with assessments before and after an induction of post-exertional malaise. 26 PASC patients, 26 ME/CFS patients and 30 matched healthy controls who have recovered from a SARS-COV-2 infection will be recruited for the study. Participants are required to visit the laboratory for a total of 5 experimental sessions, for a total duration of approximately 8 hours. Four measurements will take place within a time window of 2 weeks. On day 10, patients will fill in a digital questionnaire. The last time point will be 1 year after the start of the study. See Figure 1 for an overview of study design.
26 participants with PASC and 26 patients with ME/CFS (equal split between sexes) between the ages of 18-65 yrs will be recruited for the study. 30 healthy participants matched for age BMI and preferably physical activity levels will be included as a control group
Participants will be required to visit the laboratory on 4 separate occasions over a 2 week period immediately prior to and following a maximal exercise test. One year (± three months) we will require one additional visit. After the first visit, participants will be asked to confirm dates for the subsequent visits over the next 2 weeks face-to-face in the laboratory. Participants will be instructed not to consume alcohol or perform strenuous exercise within the 24 h preceding each exercise test, and to abstain from caffeine consumption for at least 3 h.
- STUDY POPULATION
4.1 Population 26 non-hospitalized participants with diagnosed PASC, 26 ME/CFS patients and 30 healthy participants of similar sex, age, BMI and preferably current physical activity levels between the ages of 18-65 years old will be recruited to the study. All participants with PASC will be recruited from the outpatient clinic of the Amsterdam UMC, ME/CFS patients will be recruited through ME/CFS specialists in the Netherlands, whereas healthy controls will be recruited via specific social media groups, through personal networks and/or posters. All testing will be conducted at the Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam under the direct supervision of BA or MvV from the Amsterdam UMC. Therefore, participants should be currently residing in or willing to travel to Amsterdam.
- Conditions
- LONG-COVID, Post-acute Sequelae of COVID-19, ME/CFS
- Being tested
- Bike exertion test
- Medical subject headings
- Post-Acute COVID-19 Syndrome, Fatigue Syndrome, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bike exertion testBehavioural
maximal exercise test
| Study group | Role | What they receive |
|---|---|---|
| PASC patients | Non-hospitalized covid-19 patients with Post-acute Sequelae of COVID-19 Receives: Behavioral: Bike exertion test | |
| Healthy controls | Non-hospitalized covid-19 patients without residual symptoms Receives: Behavioral: Bike exertion test | |
| ME/CFS patients | Patients with ME/CFS Receives: Behavioral: Bike exertion test |
What is being measured
The primary outcome is the main question the study is designed to answer.
Skeletal muscle mitochondrial respiratory function
Measured: 7 days
Local and systemic inflammation markers after induction of post-exertional malaise
Measured: 14 days
Secondary outcomes (3)
Heart rate variability during post-exertional malaise in LONG-COVID patients
Measured: 14 days
Exercise tolerance in LONG-COVID patients.
Measured: 7 days
Muscle oxygenation derived via near-infrared spectroscopy (NIRS) during exercise in LONG-COVID patients
Measured: 7 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Feb 2022
- Study start3 Jan 2022
- Primary completion15 Feb 2024
- Study completion1 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for LONG-COVIDStudies of the same condition, open and under way.
- More trials run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 81 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- Patient-Led Research Collaborative Long COVID
- Responsible party
- Principal investigator, Michele van Vugt, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05225688
- Sponsor's protocol ID
- NL78394.018.21
- Status last verified
- Aug 2024
- First submitted
- 24 Jan 2022
- Last updated
- 6 Aug 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Appelman B, Charlton BT, Goulding RP, Kerkhoff TJ, Breedveld EA, Noort W, Offringa C, Bloemers FW, van Weeghel M, Schomakers BV, Coelho P, Posthuma JJ, Aronica E, Joost Wiersinga W, van Vugt M, Wust RCI. Muscle abnormalities worsen after post-exertional malaise in long COVID. Nat Commun. 2024 Jan 4;15(1):17. doi: 10.1038/s41467-023-44432-3.
PubMed 38177128
Study at a glance
From the registry record, last updated by the sponsor on 6 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Skeletal Muscle Structure and Function in Relation to Post-exertional Malaise in Patients With PASC and ME/CFS
- ClinicalTrials.gov ID
- NCT05225688
- Acronym / sponsor ID
- NL78394.018.21
- Conditions
- LONG-COVID, Post-acute Sequelae of COVID-19, ME/CFS
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 81 participants (actual)
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)University, hospital or other
- Collaborators
- Patient-Led Research Collaborative Long COVID
- Study start
- 3 Jan 2022 (actual)
- Primary completion
- 15 Feb 2024 (actual)
- Study completion
- 1 Dec 2025 (estimated)
- First posted
- 4 Feb 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Rationale: A common feature in patients with Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) and Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are skeletal muscle-related symptoms, such as muscle pain, weakness, fatigue and post-exertional malaise.
Objective: The primary aim is to determine markers for skeletal muscle structure and function, and circulating factors, in patients with PASC and ME/CFS, and compare with controls. The secondary objective is to determine skeletal muscle structure and function before and after induction of post-exertional malaise, and assess the relationships between the measures obtained from muscle biopsies and parameters of exercise tolerance.
Study design: Case-control observational study
Study population: Patients with PASC, ME/CFS and healthy human volunteers, 18 - 65 yr old.
Intervention (if applicable): none
Main study parameters/endpoints: Primary outcome parameters are markers for local inflammation, viral infiltration, mitochondrial respiratory function and myokine concentrations in a muscle biopsy and venous blood before and after induction of post-exertional malaise. Heart rate variability and measures of exercise performance will also be determined.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Participants will be asked to perform physical exercise tests, give muscle biopsies (2 samples), and various blood samples. There is some extent of burden and risk associated with harvesting muscle biopsies and blood samples, however this will be mitigated by the fact that these procedures will only be carried out by trained physicians. Moreover, the scientific gain from obtaining intracellular information outweighs these relatively quick procedures with minimal discomfort afterwards. The acute risks of the physical exercise measurements are negligible. The main risk for patients is that these patients often suffer from post-exertional malaise, which causes the participants to feel fatigued for some time after the maximal exercise test. It is one of the aims to better understand post-exertional malaise.
Detailed description
- INTRODUCTION AND RATIONALE Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) are severely debilitating diseases mainly characterized by chronic fatigue, post-exertional malaise (PEM) and cognitive impairment with autonomic, neuro-endocrine, immunological and cognitive involvement(Davis et al. 2021; Deumer et al. 2021; Soares et al. 2022). The clinical presentation of both diseases is remarkably overlapping. Particularly, skeletal muscle-related complaints, such as extreme fatigue, muscle weakness and muscle pain, are symptoms that tremendously decrease the patients quality of life and overlap in both patient groups, The key symptom, PEM, distinguishes PASC and ME/CFS from other more common fatigue conditions and is characterized by worsening or relapse of symptoms (including sleep dysfunction, cognitive impairment and extreme skeletal muscle fatigue) after physical activity, which can last for days or weeks(Davis et al. 2021; Soares et al. 2022; Stussman et al. 2020). We recently reviewed the skeletal muscle alterations in both acute SARS-CoV-2 infection and patients with Long COVID, and concluded that post-exertional malaise in patients with Long COVID cannot be explained by current knowledge on skeletal muscle structure and function(Soares et al. 2022). A possible lead to the understanding of PEM in Long COVID and ME/CFS pathophysiology is provided by the observation that most cases appear to have an infectious onset(Choutka et al. 2022; Magnus et al. 2015; Tsai et al. 2014). Following SARS-CoV-2 infection, 10-30% of patients exhibit post-infectious fatigue syndrome, called Long COVID or post-COVID condition(Ballering et al. 2022). PEM is the hallmark symptom of Long COVID and ME/CFS and a criterion for CCC, ICCC and IOM case definitions. Little is known about the underlying pathophysiology of skeletal muscle abnormalities, including PEM. No treatment options are available, apart from the advice to patients to avoid exercise or exercise below an (unknown) threshold. Due to the heterogeneity of patients, these muscle-related symptoms may vary dramatically, and is likely multifactorial in nature. Whilst long-term consequences of hospitalization are known, the widespread incidence of muscle-related symptoms suggests that skeletal muscle adaptations seen in non-hospitalized patients with PASC and ME/CFS stand apart from those seen in critical illness myopathy. The muscle weakness can range from mild to severe, and such symptoms may persist long after the viral infection has resolved. The high prevalence of skeletal muscle-related symptoms hint towards structural and functional alterations in skeletal muscle in patients with PASC and ME/CFS(Kerkhoff et al. 2022; McGregor et al. 2019; Noor et al. 2021). In this study, we aim to study alterations in intracellular skeletal muscle structure and function and the immune response that will help to explain why patients with PASC and ME/CFS suffer from post-exertional fatigue.
- OBJECTIVES To obtain insight whether skeletal muscle adaptations can explain post-exertional fatigue malaise in patients with PASC and ME/CFS, the present study will address the following objectives: Primary objectives:
- To determine markers for skeletal muscle structure and function (such as mitochondrial ultrastructure and function, viral infiltration, metabolite concentrations, myokine secretion), the immune response and circulating myokines (muscle-derived molecules), in non-hospitalized patients with PASC, ME/CFS and healthy controls. Secondary objectives:
- To determine each of the above variables both before and after induction of post-exertional malaise, and assess the relationships between the measures obtained from muscle biopsies and parameters of exercise tolerance.
- STUDY DESIGN 3.1. General. Case-control study with assessments before and after an induction of post-exertional malaise. 26 PASC patients, 26 ME/CFS patients and 30 matched healthy controls who have recovered from a SARS-COV-2 infection will be recruited for the study. Participants are required to visit the laboratory for a total of 5 experimental sessions, for a total duration of approximately 8 hours. Four measurements will take place within a time window of 2 weeks. On day 10, patients will fill in a digital questionnaire. The last time point will be 1 year after the start of the study. See Figure 1 for an overview of study design.
26 participants with PASC and 26 patients with ME/CFS (equal split between sexes) between the ages of 18-65 yrs will be recruited for the study. 30 healthy participants matched for age BMI and preferably physical activity levels will be included as a control group
Participants will be required to visit the laboratory on 4 separate occasions over a 2 week period immediately prior to and following a maximal exercise test. One year (± three months) we will require one additional visit. After the first visit, participants will be asked to confirm dates for the subsequent visits over the next 2 weeks face-to-face in the laboratory. Participants will be instructed not to consume alcohol or perform strenuous exercise within the 24 h preceding each exercise test, and to abstain from caffeine consumption for at least 3 h.
- STUDY POPULATION
4.1 Population 26 non-hospitalized participants with diagnosed PASC, 26 ME/CFS patients and 30 healthy participants of similar sex, age, BMI and preferably current physical activity levels between the ages of 18-65 years old will be recruited to the study. All participants with PASC will be recruited from the outpatient clinic of the Amsterdam UMC, ME/CFS patients will be recruited through ME/CFS specialists in the Netherlands, whereas healthy controls will be recruited via specific social media groups, through personal networks and/or posters. All testing will be conducted at the Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam under the direct supervision of BA or MvV from the Amsterdam UMC. Therefore, participants should be currently residing in or willing to travel to Amsterdam.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| PASC patients | – | Behavioral: Bike exertion testNon-hospitalized covid-19 patients with Post-acute Sequelae of COVID-19 |
| Healthy controls | – | Behavioral: Bike exertion testNon-hospitalized covid-19 patients without residual symptoms |
| ME/CFS patients | – | Behavioral: Bike exertion testPatients with ME/CFS |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- 26 non-hospitalized participants with diagnosed PASC, 26 patients with ME/CFS and 30 healthy participants of similar sex, age, BMI and preferably current physical activity levels between the ages of 18-65 years old will be recruited to the study.
Key inclusion criteria (16 listed)
- In order to be eligible to participate in this study, a subject with PASC must meet all of the following criteria:
- Non-hospitalized individuals with prior confirmed diagnosis of severe acute respiratory coronavirus 2 (SARS-CoV-2) infection by reverse transcription-polymerase chain reaction testing or serology (wantai) testing
- Individuals with diagnosed PASC by a post-covid physician
- >3 months of symptoms
- Post exertional malaise, according to the DSQ-PEM questionnaire or 1:1 interview with post-covid physician
Key exclusion criteria (20 listed)
- A potential subject who meets any of the following criteria will be excluded from participation in this study:
- History of asthma, stroke, chronic obstructive pulmonary disease, congestive heart failure, heart surgery, or congenital heart diseases
- Severe illness (e.g., active malignancy, CHD, uncontrolled diabetes)
- Current treatment with drugs known to interfere with metabolism e.g. systemic corticosteroids, statins, SGLT2 inhibitors, GLP1 receptor agonists or immune modulatory drugs in the last three months.
- Severe psychiatric or mood disorders
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bike exertion testmaximal exercise test | Behavioural | Healthy controls, ME/CFS patients, PASC patients |
Primary outcome
Skeletal muscle mitochondrial respiratory function
Time frame: 7 days
Local and systemic inflammation markers after induction of post-exertional malaise
Time frame: 14 days
3 secondary outcomes
Heart rate variability during post-exertional malaise in LONG-COVID patients
Time frame: 14 days
Exercise tolerance in LONG-COVID patients.
Time frame: 7 days
Muscle oxygenation derived via near-infrared spectroscopy (NIRS) during exercise in LONG-COVID patients
Time frame: 7 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Aug 2024.
- Derived from this study: PubMed 38177128Appelman B, Charlton BT, Goulding RP, Kerkhoff TJ, Breedveld EA, Noort W, Offringa C, Bloemers FW, van Weeghel M, Schomakers BV, Coelho P, Posthuma JJ, Aronica E, Joost Wiersinga W, van Vugt M, Wust RCI. Muscle abnormalities worsen after post-exertional malaise in long COVID. Nat Commun. 2024 Jan 4;15(1):17. doi: 10.1038/s41467-023-44432-3.
- Individual participant dataSharing planned: Undecided
Related trials for LONG-COVID
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)
Not yet recruitingPhase 3
The Study of Brave-LC LDN Treatment Trial
Post-acute COVID-19 Syndrome
Active, not recruitingObservational study
Epigenetic Changes in Long COVID Patients
Long COVID-19 Syndrome, Long COVID Symptoms
Enrolling by invitationPhase 2
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
Systemic Inflammation, Neuroinflammation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of LONG-COVID and Post-acute Sequelae of COVID-19, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 16 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 6 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Skeletal muscle mitochondrial respiratory function (time frame: 7 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05225688, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2024.